Cefotetan

DB01330

small molecule approved

Deskripsi

A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.

Struktur Molekul 2D

Berat 575.619
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) In volunteers with reduced renal function, the plasma half-life of cefotetan is prolonged
Volume Distribusi * 10.4 L [elderly patients (greater than 65 years) with normal renal function] * 10.3 L [healthy volunteers (aged 25 to 28 years)]
Klirens (Clearance) * 1.8 +/- 0.1 L/h [elderly patients with normal renal function (.65 years)] * 1.8 +/- 0.3 L/h [healthy volunteers (aged 25 to 28 years)]

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

No active metabolites of cefotetan have been detected; however, small amounts (less than 7%) of cefotetan in plasma and urine may be converted to its tautomer, which has antimicrobial activity similar to the parent drug.

Rute Eliminasi

No active metabolites of cefotetan have been detected; however, small amounts (less than 7%) of cefotetan in plasma and urine may be converted to its tautomer, which has antimicrobial activity similar to the parent drug. In normal patients, from 51% to 81% of an administered dose of Cefotetan is excreted unchanged by the kidneys over a 24 hour period, which results in high and prolonged urinary concentrations.

Interaksi Makanan

1 Data
  • 1. Avoid alcohol. Alcohol can cause a disulfiram effect.

Interaksi Obat

847 Data
Probenecid The serum concentration of Cefotetan can be increased when it is combined with Probenecid.
Foscarnet The risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Foscarnet.
Mannitol The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefotetan.
Tenofovir disoproxil Cefotetan may increase the nephrotoxic activities of Tenofovir disoproxil.
Tenofovir alafenamide The serum concentration of Tenofovir alafenamide can be increased when it is combined with Cefotetan.
Tenofovir Cefotetan may increase the nephrotoxic activities of Tenofovir.
Triamterene The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Cefotetan.
Etacrynic acid The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefotetan.
Hydrochlorothiazide The risk or severity of nephrotoxicity can be increased when Hydrochlorothiazide is combined with Cefotetan.
Cyclosporine The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefotetan.
Icosapent The risk or severity of nephrotoxicity can be increased when Icosapent is combined with Cefotetan.
Cefotiam The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Cefotetan.
Mesalazine The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefotetan.
Cefmenoxime The risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Cefotetan.
Cefmetazole The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Cefotetan.
Indomethacin The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Cefotetan.
Cidofovir The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Cefotetan.
Cefpiramide The risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Cefotetan.
Ceftazidime The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Cefotetan.
Loracarbef The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Cefotetan.
Cefalotin The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Cefotetan.
Nabumetone The risk or severity of nephrotoxicity can be increased when Nabumetone is combined with Cefotetan.
Ketorolac The risk or severity of nephrotoxicity can be increased when Ketorolac is combined with Cefotetan.
Tenoxicam The risk or severity of nephrotoxicity can be increased when Tenoxicam is combined with Cefotetan.
Celecoxib The risk or severity of nephrotoxicity can be increased when Celecoxib is combined with Cefotetan.
Cefotaxime The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Cefotetan.
Tolmetin The risk or severity of nephrotoxicity can be increased when Tolmetin is combined with Cefotetan.
Rofecoxib The risk or severity of nephrotoxicity can be increased when Rofecoxib is combined with Cefotetan.
Piroxicam The risk or severity of nephrotoxicity can be increased when Piroxicam is combined with Cefotetan.
Methotrexate The risk or severity of nephrotoxicity can be increased when Methotrexate is combined with Cefotetan.
Cephalexin The risk or severity of nephrotoxicity can be increased when Cephalexin is combined with Cefotetan.
Fenoprofen The risk or severity of nephrotoxicity can be increased when Fenoprofen is combined with Cefotetan.
Valaciclovir The risk or severity of nephrotoxicity can be increased when Valaciclovir is combined with Cefotetan.
Valdecoxib The risk or severity of nephrotoxicity can be increased when Valdecoxib is combined with Cefotetan.
Diclofenac The risk or severity of nephrotoxicity can be increased when Diclofenac is combined with Cefotetan.
Sulindac The risk or severity of nephrotoxicity can be increased when Sulindac is combined with Cefotetan.
Bacitracin The risk or severity of nephrotoxicity can be increased when Bacitracin is combined with Cefotetan.
Amphotericin B The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefotetan.
Cephaloglycin The risk or severity of nephrotoxicity can be increased when Cephaloglycin is combined with Cefotetan.
Flurbiprofen The risk or severity of nephrotoxicity can be increased when Flurbiprofen is combined with Cefotetan.
Adefovir dipivoxil The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Cefotetan.
Pentamidine The risk or severity of nephrotoxicity can be increased when Pentamidine is combined with Cefotetan.
Etodolac The risk or severity of nephrotoxicity can be increased when Etodolac is combined with Cefotetan.
Mefenamic acid The risk or severity of nephrotoxicity can be increased when Mefenamic acid is combined with Cefotetan.
Acyclovir The risk or severity of nephrotoxicity can be increased when Acyclovir is combined with Cefotetan.
Naproxen The risk or severity of nephrotoxicity can be increased when Naproxen is combined with Cefotetan.
Sulfasalazine The risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Cefotetan.
Phenylbutazone The risk or severity of nephrotoxicity can be increased when Phenylbutazone is combined with Cefotetan.
Meloxicam The risk or severity of methemoglobinemia can be increased when Cefotetan is combined with Meloxicam.
Carprofen The risk or severity of nephrotoxicity can be increased when Carprofen is combined with Cefotetan.
Cefaclor The risk or severity of nephrotoxicity can be increased when Cefaclor is combined with Cefotetan.
Diflunisal The risk or severity of nephrotoxicity can be increased when Diflunisal is combined with Cefotetan.
Tacrolimus The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefotetan.
Bumetanide The risk or severity of nephrotoxicity can be increased when Bumetanide is combined with Cefotetan.
Ceforanide The risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Cefotetan.
Salicylic acid The risk or severity of nephrotoxicity can be increased when Salicylic acid is combined with Cefotetan.
Meclofenamic acid The risk or severity of nephrotoxicity can be increased when Meclofenamic acid is combined with Cefotetan.
Acetylsalicylic acid The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefotetan.
Carboplatin The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefotetan.
Oxaprozin The risk or severity of nephrotoxicity can be increased when Oxaprozin is combined with Cefotetan.
Ketoprofen The risk or severity of nephrotoxicity can be increased when Ketoprofen is combined with Cefotetan.
Balsalazide The risk or severity of nephrotoxicity can be increased when Balsalazide is combined with Cefotetan.
Ibuprofen The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefotetan.
Cefditoren The risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Cefotetan.
Atazanavir The risk or severity of nephrotoxicity can be increased when Atazanavir is combined with Cefotetan.
Colistimethate The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Cefotetan.
Cefuroxime The risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Cefotetan.
Cefapirin The risk or severity of nephrotoxicity can be increased when Cefapirin is combined with Cefotetan.
Cefadroxil The risk or severity of nephrotoxicity can be increased when Cefadroxil is combined with Cefotetan.
Cefprozil The risk or severity of nephrotoxicity can be increased when Cefprozil is combined with Cefotetan.
Ceftriaxone The risk or severity of nephrotoxicity can be increased when Ceftriaxone is combined with Cefotetan.
Olsalazine The risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Olsalazine.
Lumiracoxib The risk or severity of nephrotoxicity can be increased when Lumiracoxib is combined with Cefotetan.
Cefamandole The risk or severity of nephrotoxicity can be increased when Cefamandole is combined with Cefotetan.
Cefazolin The risk or severity of nephrotoxicity can be increased when Cefazolin is combined with Cefotetan.
Cefonicid The risk or severity of nephrotoxicity can be increased when Cefonicid is combined with Cefotetan.
Cefoperazone The risk or severity of nephrotoxicity can be increased when Cefoperazone is combined with Cefotetan.
Cefradine The risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Cefradine.
Ceftibuten The risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Ceftibuten.
Aceclofenac The risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Aceclofenac.
Benzydamine The risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Benzydamine.
Dexketoprofen The risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Dexketoprofen.
Propacetamol The risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Propacetamol.
Cefroxadine The risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Cefroxadine.
Alclofenac The risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Alclofenac.
Cefoxitin The risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Cefoxitin.
Ceftizoxime The risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Ceftizoxime.
Magnesium salicylate The risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Magnesium salicylate.
Salsalate The risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Salsalate.
Choline magnesium trisalicylate The risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Choline magnesium trisalicylate.
Cefepime The risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Cefepime.
Cefacetrile The risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Cefacetrile.
Cefpodoxime The risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Cefpodoxime.
Antrafenine The risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Antrafenine.
Aminophenazone The risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Aminophenazone.
Antipyrine The risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Antipyrine.
Tiaprofenic acid The risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Tiaprofenic acid.
Lopinavir The risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Lopinavir.
Etoricoxib The risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Etoricoxib.
Hydrolyzed Cephalothin The risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Hydrolyzed Cephalothin.

Target Protein

Penicillin-binding protein 3 pbp3

Referensi & Sumber

Synthesis reference: Maurizio Zenoni, "Process for obtaining compounds usable in the production of Cefotetan, and new compounds obtained thereby." U.S. Patent US20020169327, issued November 14, 2002.

Contoh Produk & Brand

Produk: 21 • International brands: 1
Produk
  • Cefotan
    Injection • 1 g/1mL • Intramuscular; Intravenous • US • Approved
  • Cefotan
    Injection • 2 g/1mL • Intramuscular; Intravenous • US • Approved
  • Cefotan
    Injection • 1 g/1 • Intramuscular; Intravenous • US • Approved
  • Cefotan
    Injection • 2 g/1 • Intramuscular; Intravenous • US • Approved
  • Cefotan
    Injection • 10 g/1 • Intramuscular; Intravenous • US • Approved
  • Cefotan
    Injection • 1 g/50mL • Intramuscular; Intravenous • US • Approved
  • Cefotan
    Injection • 2 g/50mL • Intramuscular; Intravenous • US • Approved
  • Cefotan
    Injection, powder, for solution • 1 g/10mL • Intramuscular; Intravenous • US • Approved
Menampilkan 8 dari 21 produk.
International Brands
  • Yamatetan

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul